LISINOPRIL

Product NDC: 31722-421
11-digit product format: 317220421
Labeler code: 31722
Product ID: 31722-421_059f5795-5de9-4a69-bced-580cf6272799
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: LISINOPRIL
Dosage form: TABLET
Route: ORAL
Labeler: Camber Pharmaceuticals Inc.
Application: ANDA203508
Marketing category: ANDA
Marketing start: 2013-11-15
Marketing end: 0000-00-00
Substance: LISINOPRIL
Active strength: 30 mg/1
Pharmacologic classes: Angiotensin Converting Enzyme Inhibitor [EPC],Angiotensin-converting Enzyme Inhibitors [MoA]
NDC exclude flag: E
Listing certified through: 2017-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 5 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	31722-421		D	Discontinued by firm	2026-10-16
excluded package	package	31722-421	31722-421-01	D	Discontinued by firm	2026-10-16
excluded package	package	31722-421	31722-421-05	D	Discontinued by firm	2026-10-16
excluded package	package	31722-421	31722-421-10	D	Discontinued by firm	2026-10-16
excluded package	package	31722-421	31722-421-30	D	Discontinued by firm	2026-10-16

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 2 of 2 · 110 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	31722-421-30	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	31722-421-01	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	31722-421-05	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	31722-421-10	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	31722-421-30	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	31722-421-01	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	31722-421-05	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	31722-421-10	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	31722-421-30	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	31722-421-01	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	31722-421-05	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	31722-421-10	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded product	product		I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	31722-421-30	I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	31722-421-01	I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	31722-421-05	I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	31722-421-10	I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded product	product		I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	31722-421-30	I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	31722-421-01	I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	31722-421-05	I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	31722-421-10	I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded product	product		I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	31722-421-30	I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	31722-421-01	I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	31722-421-05	I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	31722-421-10	I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded product	product		I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	31722-421-30	I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	31722-421-01	I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	31722-421-05	I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2021-12-27 23:28 UTC · source 2021-12-27	excluded package	package	31722-421-10	I	Inactivated by FDA	`8dfbde2a14a4…`	`c9ff85d89658…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded product	product		I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	31722-421-30	I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	31722-421-01	I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	31722-421-05	I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-12-18 03:04 UTC · source 2020-12-17	excluded package	package	31722-421-10	I	Inactivated by FDA	`e2bbac7714bc…`	`27bdfed8d636…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded product	product		I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	31722-421-30	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	31722-421-01	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	31722-421-05	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2020-06-10 20:45 UTC · source 2020-06-10	excluded package	package	31722-421-10	I	Inactivated by FDA	`9bebd1f3094a…`	`5416666fcb17…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded product	product		E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded package	package	31722-421-01	E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded package	package	31722-421-30	E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded package	package	31722-421-05	E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`
2019-12-08 06:16 UTC · source 2019-12-05	excluded package	package	31722-421-10	E	Excluded after deficient or non-compliant submission was not corrected	`110d247fa046…`	`a55b01930146…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 6 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	Approval date
A203508-001	LISINOPRIL	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29
A203508-002	LISINOPRIL	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29
A203508-003	LISINOPRIL	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29
A203508-004	LISINOPRIL	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29
A203508-005	LISINOPRIL	LISINOPRIL	30MG	TABLET / ORAL	AB	2013-10-29
A203508-006	LISINOPRIL	LISINOPRIL	40MG	TABLET / ORAL	AB	2013-10-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 6 matching rows.

Application-product, TE code table
Application-product	TE code
A203508-001	AB
A203508-002	AB
A203508-003	AB
A203508-004	AB
A203508-005	AB
A203508-006	AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 7 · 264 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	Approval date	Source SHA-256
2026-10-15 13:18:30	2026-09	A203508-001	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-002	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-003	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-004	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-005	LISINOPRIL	30MG	TABLET / ORAL	AB	2013-10-29	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-006	LISINOPRIL	40MG	TABLET / ORAL	AB	2013-10-29	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	A203508-001	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-002	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-003	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-004	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-005	LISINOPRIL	30MG	TABLET / ORAL	AB	2013-10-29	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-006	LISINOPRIL	40MG	TABLET / ORAL	AB	2013-10-29	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A203508-001	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-002	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-003	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-004	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-005	LISINOPRIL	30MG	TABLET / ORAL	AB	2013-10-29	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-006	LISINOPRIL	40MG	TABLET / ORAL	AB	2013-10-29	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A203508-001	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-002	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-003	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-004	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-005	LISINOPRIL	30MG	TABLET / ORAL	AB	2013-10-29	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-006	LISINOPRIL	40MG	TABLET / ORAL	AB	2013-10-29	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-001	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-002	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-003	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-004	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-005	LISINOPRIL	30MG	TABLET / ORAL	AB	2013-10-29	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-006	LISINOPRIL	40MG	TABLET / ORAL	AB	2013-10-29	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A203508-001	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-002	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-003	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-004	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-005	LISINOPRIL	30MG	TABLET / ORAL	AB	2013-10-29	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-006	LISINOPRIL	40MG	TABLET / ORAL	AB	2013-10-29	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-001	LISINOPRIL	2.5MG	TABLET / ORAL	AB	2013-10-29	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-002	LISINOPRIL	5MG	TABLET / ORAL	AB	2013-10-29	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-003	LISINOPRIL	10MG	TABLET / ORAL	AB	2013-10-29	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-004	LISINOPRIL	20MG	TABLET / ORAL	AB	2013-10-29	`fd3edfee7708…`

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 7 · 264 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-10-15 13:18:30	2026-09	A203508-001	AB	1	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-002	AB	1	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-003	AB	1	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-004	AB	1	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-005	AB	1	`c2088c7a36db…`
2026-10-15 13:18:30	2026-09	A203508-006	AB	1	`c2088c7a36db…`
2026-09-14 22:38:34	2026-08	A203508-001	AB	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-002	AB	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-003	AB	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-004	AB	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-005	AB	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A203508-006	AB	1	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A203508-001	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-002	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-003	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-004	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-005	AB	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A203508-006	AB	1	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A203508-001	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-002	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-003	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-004	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-005	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A203508-006	AB	1	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-001	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-002	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-003	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-004	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-005	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A203508-006	AB	1	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A203508-001	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-002	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-003	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-004	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-005	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A203508-006	AB	1	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-001	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-002	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-003	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A203508-004	AB	1	`fd3edfee7708…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDC	Effective	Related label
31722-421-01	2025-02-20	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988
31722-421-05	2025-02-20	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988
31722-421-10	2025-02-20	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988
31722-421-30	2025-02-20	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988
31722-421-01	2020-01-31	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988
31722-421-05	2020-01-31	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988
31722-421-10	2020-01-31	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988
31722-421-30	2020-01-31	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Lisinopril Tablets safely and effectively. See full prescribing information for Lisinopril Tablets Lisinopril Tablets, USP for oral use Initial U.S. Approval: 1988

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
31722-421-01	EA - Each	31722-421	74f1bb38-3220-478d-8422-26c3a78db006	1	2014-02-04
31722-421-10	EA - Each	31722-421	0b2b8b5f-45ba-4ee9-9bdc-e19a566bfed6	1	2014-02-04

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
LISINOPRIL	ACTIVE INGREDIENT	E7199S1YWR	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2
LISINOPRIL ANHYDROUS	ACTIVE MOIETY	7Q3P4BS2FD	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2
COLLOIDAL SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2
FERRIC OXIDE RED	INACTIVE INGREDIENT	1K09F3G675	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2
FERRIC OXIDE YELLOW	INACTIVE INGREDIENT	EX438O2MRT	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2
LACTOSE MONOHYDRATE	INACTIVE INGREDIENT	EWQ57Q8I5X	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2
MAGNESIUM STEARATE	INACTIVE INGREDIENT	70097M6I30	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2
STARCH, CORN	INACTIVE INGREDIENT	O8232NY3SJ	LISINOPRIL TABLET [CAMBER PHARMACEUTICALS INC.]	2

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
lisinopril	LISINOPRIL	Aphena Pharma Solutions - Tennessee, LLC	32eb18bc-a80d-4de1-8f38-e591d8f66870	2021-08-10	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 203508 application number: ANDA203508
lisinopril	LISINOPRIL	Exelan Pharmaceuticals Inc.	1bc69836-a659-4e3b-84a7-a00b7c4dc268	2020-09-28	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 203508 application number: ANDA203508

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
E7199S1YWR	LISINOPRIL	83915-83-7	LISINOPRIL

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
LISINOPRIL	Camber Pharmaceuticals Inc. \| InvaGen Pharmaceuticals Inc.	2015-04-19	HUMAN PRESCRIPTION DRUG LABEL	2